https://www.selleckchem.com/pr....oducts/Phenformin-hy
A linear mixed model and a type III anova with Tukey's post hoc comparison was performed (p 0.05). Significant increases in SAP (28% and 90%), MAP (27% and 90%) and DAP (33% and 97%) were measured with medium and high dose treatments, respectively (p 0.001), with no changes in CO. HR decreased and stroke volume increased significantly with high dose treatment (by 17% and 15%, respectively; p 0.05). No arrhythmias were noticed with NE treatments. The infusion of NE at 0.5-1.0 μg kg minute is a potentially
Like
Comment
Share
